4-(1-哌啶基)苯硼酸频哪酯 | 852227-96-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(1-哌啶基)苯硼酸频哪酯
• 中文别名: 1-[4-(4,4,5,5-四甲基-1,3,2-二氧硼烷-2-基)苯基]哌啶；1-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]哌啶
• 英文名称: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine
• 英文别名: 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine
• CAS: 852227-96-4
• 化学式: C₁₇H₂₆BNO₂
• mdl: MFCD07368524
• 分子量: 287.21
• InChiKey: OTOKWHGMHAAFRM-UHFFFAOYSA-N

物化性质

• 熔点：
  87 °C
• 沸点：
  411.2±28.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.89
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.647
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P270,P271,P302+P352,P305+P351+P338,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine
CAS number: 852227-96-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H26BNO2
Molecular weight: 287.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(1-哌啶基)苯硼酸频哪酯 在 copper(I) bromide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  铜促进硼酯和二氮杂环丁酮的 C-N 偶联：一种制备芳基脲的方法

  摘要：

  描述了一种新的铜促进硼酯和二叔丁基二氮杂环丁酮之间的 C-N 偶联。在温和条件下可以很容易地获得多种芳基脲，产率高达 92%。

  DOI：

  10.1021/acs.orglett.1c03468
• 作为产物：
  描述：

  N-苯基哌啶 在 四氢噻吩 、 三(五氟苯基)硼烷 、 三乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 生成 4-(1-哌啶基)苯硼酸频哪酯
  参考文献：
  名称：

  Catalytic Aromatic Borylation via in situ-Generated Borenium Species

  摘要：

  We have developed a catalytic direct borylation of arenes via in situ-generated borenium species. The choice of appropriate Lewis base was crucial to achieve the catalytic system. Electron-rich arenes were borylated in a regioselective manner.This paper is dedicated to Prof. Masakatsu Shibasaki on the occasion of his 70th birthday and for his outstanding achievement in asymmetric cooperative catalysis.

  DOI：

  10.3987/com-16-s(s)43

文献信息

• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• Photo-induced thiolate catalytic activation of inert Caryl-hetero bonds for radical borylation
  作者：Shun Wang、Hua Wang、Burkhard König

  DOI：10.1016/j.chempr.2021.04.016

  日期：2021.6

  the activation of bonds with high bond dissociation energy and to substrates with high reduction potentials. Herein, we introduce a novel photocatalytic strategy for the activation of inert substituted arenes for aryl borylation by using thiolate as a catalyst. This catalytic system exhibits strong reducing ability and engages non-activated Caryl–F, Caryl–X, Caryl–O, Caryl–N, and Caryl–S bonds in productive

  目前正致力于获得具有高氧化还原能力的光氧化还原催化剂。然而，将目前建立的方法应用于具有高键离解能的键的活化和具有高还原电位的基材仍然具有挑战性。在此，我们介绍了一种新的光催化策略，通过使用硫醇盐作为催化剂来活化惰性取代芳烃以进行芳基硼化。该催化体系具有很强的还原能力，可与未活化的C芳基-F、C芳基-X、C芳基-O、C芳基-N和C芳基结合-S 键用于生产性自由基硼化反应，从而扩大了可用的芳基自由基前体范围。尽管具有很高的还原能力，但该方法具有广泛的底物范围和良好的官能团耐受性。光谱研究和控制实验表明，电荷转移复合物的形成是激活底物的关键步骤。
• Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors
  作者：Yiqing Yang、Lin Cao、Hongying Gao、Yue Wu、Yaxin Wang、Fang Fang、Tianlong Lan、Zhiyong Lou、Yu Rao

  DOI：10.1021/acs.jmedchem.9b00091

  日期：2019.4.25

  exploited by phenotypic screening to discover new antiviral inhibitors. After optimizations from hit to lead, a novel potent small molecule (RYL-634) was identified, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis C virus, dengue virus, Zika virus, chikungunya virus, enterovirus 71, human immunodeficiency virus, respiratory syncytial virus

  病毒感染正在增加，并且可能是持久的全球风险。在这项研究中，通过表型筛选开发了一个化学文库，以发现新的抗病毒抑制剂。经过从头到尾的优化后，鉴定出一种新型的强效小分子（RYL-634），它对各种致病性病毒（包括丙型肝炎病毒，登革热病毒，寨卡病毒，基孔肯雅病毒，肠病毒71，人免疫缺陷病毒，呼吸道合胞病毒等。通过结合基于活性的蛋白质谱分析和其他技术，进一步探索了RYL-634的作用机理和潜在靶标。最后，人二氢乳清酸酯脱氢酶被证实是RYL-634的主要靶标。在使用RYL-634进行压力选择时，我们没有观察到任何突变抗性，并且与某些获得美国食品药品监督管理局（FDA）批准的药物具有很强的协同作用。因此，有很大的潜力开发基于RYL-634的新型广谱抗病毒药。
• Derisking the Cu-Mediated ¹⁸F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands
  作者：Nicholas J. Taylor、Enrico Emer、Sean Preshlock、Michael Schedler、Matthew Tredwell、Stefan Verhoog、Joel Mercier、Christophe Genicot、Véronique Gouverneur

  DOI：10.1021/jacs.7b03131

  日期：2017.6.21

  Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach

  用氟 18 (18F) 标记的分子用于正电子发射断层扫描，以可视化、表征和测量体内的生物过程。尽管最近在将 18F 掺入芳烃方面取得了进展，但开发通用且有效的方法来标记药物发现计划所需的放射性配体仍然是一项重大任务。这个完整的描述描述了杂环正电子发射断层扫描 (PET) 放射性配体的放射合成方法，使用铜介导的 18F 氟化芳基硼试剂与 18F 氟化物作为模型反应。该方法基于一项研究，该研究检查了药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 18F-氟化效率，以及超过 50 种（杂）芳基硼酸酯的标记。这组数据允许将这种去风险策略应用于七种结构复杂的药物相关含杂环分子的成功放射合成。
• [EN] SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE SULFONAMIDE EN TANT QU'INHIBITEURS DE STAT3 POUR LE TRAITEMENT DE MALADIES PROLIFÉRANTES
  申请人：KING S COLLEGE LONDON

  公开号：WO2019030538A1

  公开（公告）日：2019-02-14

  The invention relates to derivatives of formula (I) where R1, R2, R3, R4, R5, X and m are as defined in the specification. These compounds which have therapeutic activity, in particular, as STAT3 inhibitors and so are useful in the treatment of proliferative diseases or conditions such as cancer. Methods for producing these compounds, novel intermediates used in the methods, pharmaceutical compositions containing them and their use in therapy form further aspects of the invention.

  该发明涉及到公式(I)的衍生物，其中R1、R2、R3、R4、R5、X和m的定义如规范中所述。这些化合物具有治疗活性，特别是作为STAT3抑制剂，在治疗增殖性疾病或状况，如癌症方面具有用途。制备这些化合物的方法，方法中使用的新型中间体，含有它们的药物组合物以及它们在治疗中的使用等方面也是该发明的进一步方面。